(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(-0.08%) $78.94
(5.43%) $2.04
(0.08%) $2 312.90
(0.50%) $26.88
(0.77%) $962.30
(-0.08%) $0.932
(-0.34%) $10.99
(-0.10%) $0.798
(-1.35%) $92.01
Live Chart Being Loaded With Signals
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States...
Stats | |
---|---|
Šios dienos apimtis | 11 099.00 |
Vidutinė apimtis | 25 908.00 |
Rinkos kapitalizacija | 18.28M |
EPS | $0 ( 2024-03-15 ) |
Kita pelno data | ( $0 ) 2024-07-29 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.460 |
ATR14 | $0.0220 (1.02%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-20 | Weinstein Robert | Buy | 61 248 | Stock Option (Right to Buy) |
2023-11-20 | Walker Wayne Remell | Buy | 61 248 | Stock Option (Right to Buy) |
2023-11-20 | Trujillo Carlos | Buy | 85 000 | Stock Option (Right to Buy) |
2023-11-20 | Silverman Joshua | Buy | 170 000 | Stock Option (Right to Buy) |
2023-11-20 | Schechter Jonathan | Buy | 61 248 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
56.79 |
Last 54 transactions |
Buy: 749 992 | Sell: 831 346 |
PharmaCyte Biotech, Inc. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
PharmaCyte Biotech, Inc. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-0.220 |
FY | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-0.220 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-0.260 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-2.45 |
Financial Reports:
No articles found.
PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.